Nanologica Ab · OMXSTO:NICA
Nanologica Ab — Q1 2024 Earnings Presentation
27 slides from Nanologica Ab's earnings presentation, Apr 26, 2024
Slide 1: Interim Report Q1 2024
INTERIM REPORT Q1 2024 N A N O LO G I C A A B ( PU B L )
Slide 2: Period in Short
PERIOD IN SHORT FINANCIAL SUMMARY • Net sales for the first quarter amounted to TSEK 5,037 (355) • The operating loss for the quarter amounted to TSEK -15,331 (-10,720). • Loss after tax for the quarter amounted to TSEK -16,734 (-12,094) • Earnings per share before and after dilution were SEK -0.46
Slide 3: CEO Comment
CEO COMMENT The year has started both positively and negatively. On a positive note, we have started delivering chromatography media to customers and we achieved net sales of MSEK 5 in the first quarter. This is the company's highest sales of chromatography products in a single quarter to date and i
Slide 4: CEO Comment (continued)
During the quarter, we also noted with interest price increases in certain segments of the chromatography media market. Of course, this is also beneficial for our business. The rights issue that we carried out during the quarter provided the company with approximately MSEK 40 in cash payment and set
Slide 5: This is Nanologica
THIS IS NANOLOGICA Better and cheaper medicine to a larger number of patients Nanologica is a Swedish life science tools company that provides consumables to pharmaceutical manufacturers. With a foundation in materials science and nanotechnology, the company has developed an expertise in chromatogra
Slide 6: Five Reasons to Invest in Nanologica
FIVE REASONS TO INVEST IN NANOLOGICA By developing chromatography products that enable pharmaceutical manufacturers to streamline their production and lower their production costs, Nanologica not only strives to create value for its shareholders, but also to contribute to more patients having access
Slide 7: Business Area Chromatography
BUSINESS AREA CHROMATOGRAPHY The largest delivery during the quarter was Several initiatives aimed at optimizing lead NLAB Siv , Nanologica's first non-silica-based times and production economy in the large- purification media. NLAB Siv is a scale production of silica have been initiated. chromatogr
Slide 8: Operating Income and Result, Investments, Liquidity
OPERATING INCOME AND RESULT 1,332 at the beginning of the year. Net sales for the first quarter amounted to TSEK 5,037 (355), of which preparative The book value of right-of-use assets amounted chromatography amounted to TSEK 4,815 and on the balance sheet date to TSEK 12,504 analytical chromatograp
Slide 9: Rights Issue, Employees, Patents
mainly related to laboratory equipment and in 2024. Nanologica lacks significant seasonal patents. Cash flow from financing activities variations amounted during the quarter to TSEK 26,902 (- 1,213). During the first quarter, parts of the proceeds from the completed rights issue were EMPLOYEES AND O
Slide 10: Financial Calendar, Annual General Meeting, Future Prospects
31, the shares from the new share issue are not warrant shall entail a right to subscribe for one reported. share in the company at a subscription price equivalent to SEK 30 during the period 1 August After registration of the rights issue, the number 2026 to 30 November 2026. Based on the of shares
Slide 11: External Factors, Auditors Review, Assurance
regulatory risks, such as financing of upscaling term of the loans. Regarding fluctuations in projects, commercialization, dependence on exchange rates, the company's production and partners, research, trademarks, patents and commitments are mainly in British pounds and external requirements, and op
Slide 12: Financial Reports and Notes
FINANCIAL REPORTS AND NOTES
Slide 13: Consolidated Income Statement
CONSOLIDATED INCOME STATEMENT 2024 2023 2023 Amounts in TSEK Jan - Mar Jan - Mar Jan - Dec Net sales 5 037 355 1 443 Change in inventories, finished goods 2 061 284 2 080 Capitalized work for own use 0 1 402 3 229 Other operating income 25 41 494 Operating expenses Raw materials and consumables -5 1
Slide 14: Consolidated Balance Sheet
CONSOLIDATED BALANCE SHEET 2024 2023 2023 Amounts in TSEK Mar 31 Mar 31 Dec 31 ASSETS Fixed assets Intangible fixed assets Capitalized expenditure for research and development and similar 20 141 21 227 5 292 Concessions, patents, licenses, trademarks and similar rights 1 423 1 516 1 225 Tangible fix
Slide 15: Consolidated Statement of Changes in Equity
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 2024 2023 2023 Amounts in TSEK Jan - Mar Jan - Mar Jan - Dec Total equity at the beginning of the period -1 898 73 158 73 158 Profit/loss for the year -16 769 -12 094 -75 157 Other comprehensive income 0 0 0 Total comprehensive income for the period -16 76
Slide 16: Consolidated Cash Flow Statement
CONSOLIDATED CASH FLOW STATEMENT 2024 2023 2023 Amounts in TSEK Jan - Mar Jan - Mar Jan - Dec Operating activities Operating profit/loss -15 331 -10 720 -69 963 Adjustment for items not affecting cash flow -414 3 261 18 959 Write-down of the Sterling contract 4 075 9 785 Interest received 36 1 464 I
Slide 17: Notes
NOTES NOTE 1 GENERAL INFORMATION This report covers the Swedish parent company Nanologica AB (publ), corporate registration number 556664-5023, and its subsidiaries. The parent company is a limited liability company with its registered office in Stockholm, Sweden. The address of the main office is F
Slide 18: Operating Segments
Nanologica currently has one operating segment in the group; Chromatography. Up until 2023, there was a second operating segment, Drug Development, in which operations were discontinued at the end of 2023. Ongoing external collaborations based on the company's technology platform and patents are ong
Slide 19: Note: Distribution of Income
NOTE 5 DISTRIBUTION OF INCOME Nanologica's distribution of revenues for sales of goods and provision of services at a specific time and over time divided per geographic market and reported separately for major customers. All revenue is at a specific time. 2024 2023 2023 Composition of net sales, per
Slide 20: Information Regarding Loans
Information regarding loans Loans from Flerie Invest AB amounted to MSEK 67 on the balance sheet day and were raised on market terms. Loan 1 totaling MSEK 17 was raised during autumn 2019 and spring 2020. Loan 2 totaling MSEK 50 was raised during the first half of 2022. The interest rate for the loa
Slide 21: Alternative Performance Measures
Equity/assets ratio* Equity in relation to the balance sheet total. Equity per share* Equity divided by the number of shares outstanding at the end of the period. Average number of shares during the period Calculated as an average of the number of ordinary shares outstanding during the reporting per
Slide 22: Group Quarterly Data
GROUP QUARTERLY DATA Amounts in TSEK unless otherwise stated 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 Statement of comprehensive income Net sales 5 037 75 342 672 355 674 401 210 Total operating expenses -22 453 -38 265 -10 467 -15 676 -12 801 -15 326 -11 421 -13 796 Operating
Slide 23: Income Statement for the Parent Company
INCOME STATEMENT FOR THE PARENT COMPANY 2024 2023 2023 Amounts in TSEK Jan - Mar Jan - Mar Jan - Dec Net sales 5 037 355 1 443 Change in inventories, finished goods 2 061 284 2 080 Capitalized work for own use 0 1 402 3 229 Other operating income 25 41 494 Operating expenses Raw materials and consum
Slide 24: Balance Sheet for the Parent Company
BALANCE SHEET FOR THE PARENT COMPANY 2024 2023 2023 Amounts in TSEK 31 Mar Mar 31 31 Dec ASSETS Fixed assets Intangible assets Capitalized expenditure for research and development and similar 24 679 29 938 27 391 Concessions, patents, licenses, trademarks and similar rights 1 423 1 516 1 332 Total i
Slide 25: Balance Sheet for the Parent Company (equity and liabilities)
BALANCE SHEET FOR THE PARENT COMPANY 2024 2023 2023 Amounts in TSEK 31 Mar Mar 31 31 Dec EQUITY AND LIABILITIES Equity Share capital 14 821 14 821 14 821 Fund for development expenditure 607 6 585 748 Total restricted equity 17 233 21 406 15 569 Non-restricted equity Share premium reserve 336 232 30
Slide 26: Parent Company Changes in Equity and Cash Flow
STATEMENT OF CHANGES IN EQUITY FOR THE PARENT COMPANY 2024 2023 2023 Amounts in TSEK Jan - Mar Jan - Mar Jan - Dec Total equity at the beginning of the period -6 940 68 840 68 840 Non registered share capital 1 805 Off set loans 6 176 0 0 Rights issue 27 908 Premiums for issued / repurchased warrant
Slide 27: Nanologica AB (publ) contact details
Nanologica AB (publ) Forskargatan 20 G SE-151 36 Södertälje, Sweden Ph: +46-8-410 749 49 www.nanologica.com